Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study
European Journal of Endocrinology · 2024
DOI: 10.1093/ejendo/lvae045 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Miguel Sampedro-Nuñez und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma …. Hauptthemen laut MEDLINE: Acromegaly, Growth Hormone-Secreting Pituitary Adenoma, Neoplasm Invasiveness, Adenoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Spanish Society of Endocrinology and Nutrition (SEEN), Molecular Registry of Pituitary Adenomas, Novartis and the SEEN Foundation.
Abstract (Originalsprache)
Introduction
Growth hormone (GH)-secreting pituitary tumors (GHomas) are the most common acromegaly cause. At diagnosis, most of them are macroadenomas, and up to 56% display cavernous sinus invasion. Biomarker assessment associated with tumor growth and invasion is important to optimize their management.
Objectives
The study aims to identify clinical/hormonal/molecular biomarkers associated with tumor size and invasiveness in GHomas and to analyze the influence of pre-treatment with somatostatin analogs (SSAs) or dopamine agonists (DAs) in key molecular biomarker expression.
Methods
Clinical/analytical/radiological variables were evaluated in 192 patients from the REMAH study (ambispective multicenter post-surgery study of the Spanish Society of Endocrinology and Nutrition). The expression of somatostatin/ghrelin/dopamine system components and key pituitary/proliferation markers was evaluated in GHomas after the first surgery. Univariate/multivariate regression studies were performed to identify association between variables.
Results
Eighty percent of patients harbor macroadenomas (63.8% with extrasellar growth). Associations between larger and more invasive GHomas with younger age, visual abnormalities, higher IGF1 levels, extrasellar/suprasellar growth, and/or cavernous sinus invasion were found. Higher GH1 and lower PRL/POMC/CGA/AVPR1B/DRD2T/DRD2L expression levels (P < .05) were associated with tumor invasiveness. Least Absolute Shrinkage and Selection Operator’s penalized regression identified combinations of clinical and molecular features with areas under the curve between 0.67 and 0.82. Pre-operative therapy with DA or SSAs did not alter the expression of any of the markers analyzed except for DRD1/AVPR1B (up-regulated with DA) and FSHB/CRHR1 (down-regulated with SSAs).
Conclusions
A specific combination of clinical/analytical/molecular variables was found to be associated with tumor invasiveness and growth capacity in GHomas. Pre-treatment with first-line drugs for acromegaly did not significantly modify the expression of the most relevant biomarkers in our association model. These findings provide valuable insights for risk stratification and personalized management of GHomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedade…
- Endocrinology and Nutrition Service, Reina Sofia University Hospital, Córboba, Spain.
- Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córboba, Spain.
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Córdoba, Spain.
- Reina Sofia University Hospital, Córdoba, Spain.
ORCID-Profile: Aura Dulcinea Herrera-Martínez, Mercedes Robledo, Montserrat Marqués-Pamies, Marta Araujo-Castro, Sonia Gaztambide, Justo P Castaño, Mónica Marazuela, Raúl M Luque
Förderung
- Spanish Society of Endocrinology and Nutrition (SEEN)
- Molecular Registry of Pituitary Adenomas
- Novartis and the SEEN Foundation
- Comunidad de Madrid
Zitieren
APA
Sampedro-Nuñez, M., Herrera-Martínez, A. D., Ibáñez-Costa, A., Rivero-Cortés, E., Venegas, E., Robledo, M., Martínez-Hernández, R., García-Martínez, A., Gil, J., Jordà, M., López-Fernández, J., Gavilán, I., Maraver, S., Marqués-Pamies, M., Cámara, R., Fajardo-Montañana, C., Valassi, E., Dios, E., Aulinas, A., …, & REMAH investigators (2024). Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae045
Vancouver
Sampedro-Nuñez M, Herrera-Martínez AD, Ibáñez-Costa A, Rivero-Cortés E, Venegas E, Robledo M, et al. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae045
BibTeX
@article{SampedroNuez2024,
author = {Sampedro-Nuñez, Miguel and Herrera-Martínez, Aura Dulcinea and Ibáñez-Costa, Alejandro and Rivero-Cortés, Esther and Venegas, Eva and Robledo, Mercedes and Martínez-Hernández, Rebeca and García-Martínez, Araceli and Gil, Joan and Jordà, Mireia and López-Fernández, Judith and Gavilán, Inmaculada and Maraver, Silvia and Marqués-Pamies, Montserrat and Cámara, Rosa and Fajardo-Montañana, Carmen and Valassi, Elena and Dios, Elena and Aulinas, Anna and Biagetti, Betina and Álvarez Escola, Cristina and Araujo-Castro, Marta and Blanco, Concepción and Paz, de Miguel and Villar-Taibo, Rocío and Álvarez, Clara V and Gaztambide, Sonia and Webb, Susan M and Castaño, Luis and Bernabéu, Ignacio and Picó, Antonio and Gálvez, María-Ángeles and Soto-Moreno, Alfonso and Puig-Domingo, Manel and Castaño, Justo P and Marazuela, Mónica and Luque, Raúl M and REMAH investigators, REMAH investigators},
title = {Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study},
journal = {European Journal of Endocrinology},
year = {2024},
doi = {10.1093/ejendo/lvae045}
}
EUVIMED